ClinicalTrials.gg
CompletedNCT04519567Updated Jun 30, 2021

Multiple Ascending Dose Study of CTI-1601 Versus Placebo in Subjects With Friedreich's Ataxia

A Phase 1 interventional study of CTI-1601 and Placebo in Friedreich Ataxia, sponsored by Larimar Therapeutics, Inc.. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-06-30.

Sponsored by Larimar Therapeutics, Inc. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Mar 2021, 5 years 8 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
27
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 71 studies in Friedreich Ataxia with a site in United States — 18 open to participants now, 25 under way, 4 of them phase 3. Friedreich Ataxia · United States.

Enrollment
30th of 49
27 · median 32
Started
2020
with 2 others
Phase 1
15 of 71
4 open now
Registered
38th of 71
by date
Lead sponsor
8 of 71
Larimar Therapeutics, Inc.

Among the 71 studies in Friedreich Ataxia with a site in United States, this one is the 30th largest by enrollment of the 49 interventional ones that give a count, is one of 3 that started in 2020, is one of 15 in phase 1, and was the 38th registered.

Friedreich Ataxia

111 studies on the registry are indexed under Friedreich Ataxia; 28 are open to participants now.

Browse Friedreich Ataxia studies →

Open to participants now

18 of the 71 studies in Friedreich Ataxia with a site in United States are open now. Recruiting first, the newest first:

13 more — sign in →

All 18 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 18 Friedreich Ataxia studies recruiting now, 9 (50%) set no upper age limit and 9 (50%) stop at 75 or younger; 15 take children under 18; 3 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 71 studies in Friedreich Ataxia with a site in United States, or all of them as a file.
02

Study summary

To evaluate the safety and tolerability of multiple ascending doses of CTI-1601 in participants with Friedreich's ataxia

Read the detailed description

Multiple Ascending Dose (MAD), Double-Blind, Placebo Controlled Study.

To evaluate the safety and tolerability of multiple ascending doses of CTI-1601 in subjects with Friedreich's ataxia.

Secondary Objectives:

  1. To evaluate the pharmacokinetics (PK) of CTI-1601 following, multiple, increasing, doses of subcutaneously (SC) administered CTI-1601.
  2. To evaluate the pharmacodynamics (PD) of CTI-1601 following, multiple, increasing, doses of SC administered CTI-1601.
03

Conditions studied

  • Friedreich Ataxia

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subject has genetically confirmed Friedreich's ataxia diagnosis manifested by homozygous GAA repeat expansions, with repeat sizing (if available) included on diagnostic report.
  2. Subject is male or female, 18 years of age or older at screening
  3. Subject must have a mFARS_neuro score ≥ 20 and be able to traverse a distance of 25 feet with or without some assistive device (cane, walker, crutches, self-propelled wheelchair) and (a) be able to sit upright with thighs together and arms crossed without requiring support on more than two sides; (b) be able to transfer from bed to chair independently or with assistance if, in the opinion of the principal investigator, the degree of physical disability does not result in undue risk to the subject while participating in the study; and (c) perform basic daily care, such as feeding themselves and personal hygiene, with minimal assistance.
  4. Subjects must weigh > 40 kilograms (kg).

Exclusion criteria

Exclusion Criteria:

  1. Subjects who had a serious adverse event (SAE), an adverse event (AE) that is Grade 3 or higher according to the (CTCAE), version 5.0 (or higher), or an AE considered during participation in CLIN-1601-101 (NCT04176991).
  2. Subjects who are confirmed as compound heterozygous (GAA repeat expansion on only one allele) for Friedreich's ataxia.
  3. Subject use of drug (other than CTI-1601) or device within 90 days prior to screening.
  4. Subject requires use of amiodarone.
  5. Subject used erythropoietin, etravirine, or gamma interferon within 3 months prior to screening.
  6. Subject use of daily biotin supplementation that exceeds 30 mcg/day, either as part of a multivitamin or as a standalone supplement, within 7 days prior to study drug administration and/or throughout the entire study.
  7. Subject has clinically significant arrhythmia on (ECG), or evidence of predisposition to significant ventricular arrhythmia on ECG, or evidence of active and unstable coronary artery disease.
  8. Male subject who has a corrected for heart rate using Fridericia's formula (QTcF) > 450 milliseconds or female subject who has a QTcF > 470 milliseconds on an ECG.
  9. Subject has a screening echocardiogram \< 45 percent.
  10. Subject has a history of aspiration, aspiration pneumonia, or recurrent episodes of pneumonia (greater than or equal to 2 episodes of pneumonia) within the last 12 months.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
27 participants (actual)

Study arms

  • Experimental
    CTI-1601

    Biological: CTI-1601

  • Placebo comparator
    Placebo

    Biological: Placebo

Interventions

  • BiologicalCTI-1601

    CTI-1601 is a recombinant fusion protein and is intended to deliver human frataxin, the protein deficient in Friedreich's ataxia

  • BiologicalPlacebo

    Placebo Comparator

06

What researchers measure

Primary outcomes

  1. Number of Participants with Treatment Emergent Adverse Events

    Overall summary of Participants with Treatment Emergent Adverse Events

    Time frame: Through study completion, an average of 75 days

  2. Number of Participants with Treatment Emergent Adverse Events by System Organ Classification and Preferred Term

    Overall summary of Participants with Treatment Emergent Adverse Events by System Organ Classification (MedDRA version 23.0)

    Time frame: Through study completion, an average of 75 days

Secondary outcomes

  1. Pharmacokinetics - Maximum observed plasma concentration after multiple doses

    Summary assessment of changes in the maximum observed plasma concentration after multiple doses

    Time frame: At baseline and up to 15 days

  2. Pharmacokinetics - Minimum or "trough" plasma concentration after multiple doses

    Summary assessment of minimum or "trough" observed plasma concentration after multiple doses just prior to the administration of a subsequent dose

    Time frame: At baseline and up to 15 days

  3. Pharmacokinetics - Area under the concentration time curve (AUC) from time 0 through the last measurable time point

    Summary assessment of changes in the AUC from time 0 to the last measurable time point and during the dosing interval

    Time frame: At baseline and up to 15 days

  4. Pharmacokinetics - Terminal half-life estimation

    Summary assessment of changes in the terminal half-life estimation

    Time frame: At baseline and up to 15 days

  5. Changes from Baseline in Frataxin Levels in Buccal Cell

    Summary assessment of changes in frataxin levels in buccal cells

    Time frame: At baseline and up to 43 days

  6. Changes from Baseline in Levels of Protein Markers in Buccal Cell

    Summary assessment of changes in levels of protein markers in buccal cells

    Time frame: At baseline and up to 43 days

  7. Changes from Baseline in Gene Expression in Buccal Cells

    Summary assessment of changes in gene expression in buccal cells

    Time frame: At baseline and up to 43 days

  8. Changes from Baseline in Frataxin Levels in Platelets

    Summary assessment of changes in frataxin levels in platelets

    Time frame: At baseline and up to 13 days

  9. Changes from Baseline in Gene Expression in Whole Blood

    Summary assessment of changes in gene expression in whole blood

    Time frame: At baseline and up to 16 days

  10. Changes from Baseline in Frataxin Levels in Skin Punch Cells

    Summary assessment of changes in frataxin levels in skin punch cells

    Time frame: At baseline and up to 13 days

  11. Changes from Baseline in Levels of Defined Protein Markers in Blood

    Summary assessment of changes in levels of defined protein markers in blood

    Time frame: At baseline and up to 16 days

  12. Changes from Baseline in Levels of Specialized Lipids in Blood

    Summary assessment of changes in levels of specialized lipids in blood

    Time frame: At baseline and up to 16 days

07

Study locations

1 site
  • Clinilabs Drug Development Corporation
    Eatontown, New Jersey 07724, United States
08

References and documents

Publications

  • Koeppen AH. Friedreich's ataxia: pathology, pathogenesis, and molecular genetics. J Neurol Sci. 2011 Apr 15;303(1-2):1-12. doi: 10.1016/j.jns.2011.01.010. PubMed 21315377 ↗
  • Delatycki MB, Corben LA. Clinical features of Friedreich ataxia. J Child Neurol. 2012 Sep;27(9):1133-7. doi: 10.1177/0883073812448230. Epub 2012 Jun 29. PubMed 22752493 ↗
  • Goodkin DE, Hertsgaard D, Seminary J. Upper extremity function in multiple sclerosis: improving assessment sensitivity with box-and-block and nine-hole peg tests. Arch Phys Med Rehabil. 1988 Oct;69(10):850-4. PubMed 3178453 ↗
  • Rudick R, Antel J, Confavreux C, Cutter G, Ellison G, Fischer J, Lublin F, Miller A, Petkau J, Rao S, Reingold S, Syndulko K, Thompson A, Wallenberg J, Weinshenker B, Willoughby E. Clinical outcomes assessment in multiple sclerosis. Ann Neurol. 1996 Sep;40(3):469-79. doi: 10.1002/ana.410400321. PubMed 8797541 ↗
  • Plasterer HL, Deutsch EC, Belmonte M, Egan E, Lynch DR, Rusche JR. Development of frataxin gene expression measures for the evaluation of experimental treatments in Friedreich's ataxia. PLoS One. 2013 May 17;8(5):e63958. doi: 10.1371/journal.pone.0063958. Print 2013. PubMed 23691127 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2020 to primary completion in Mar 2021, 7 months.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 17, 2020
First posted
Aug 19, 2020
StartActual
Jul 31, 2020
Primary completionActual
Mar 16, 2021
CompletionActual
Mar 16, 2021
Last update
Jun 30, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 30, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04519567
Lead sponsor
Larimar Therapeutics, Inc.
Collaborators
Veristat, Inc., Metrum Research Group, LLC
Responsible party
Sponsor
First posted
Aug 19, 2020
Start date
Jul 31, 2020
Primary completion
Mar 16, 2021
Completion
Mar 16, 2021
Last update
Jun 30, 2021

Study contacts

Magdy Shenouda, M.D.
principal investigator · Clinilabs, Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nomlabofusp

Start the discussion